Balansio on nyt FreeStyle Libre yhteensopiva!

Libre-Balansio-integration-FIN.png

Julkaisuvapaa lehdistötiedote 25.4.2018
English below

Quattro Folian Balansio® -palvelu tarjoaa Abbottin valtuuttamana FreeStyle Libre® tiedot osaksi diabeteksen omahoitotietoja kliiniseen käyttöön. 

Quattro Folia, Espoo, Suomi., 25 huhtikuuta 2018 – Quattro Folia ilmoitti tänään, että heidän Balansio -palvelu on auktorisoitu Abbottin toimesta vastaanottamaan tietoa FreeStyle LibreLinkin kautta Suomen markkinalla. Integraation tuomat mahdollisuudet käyttäjille ovat saatavilla 23. Huhtikuuta alkaen, Balansion uuden version ilmestymisen yhteydessä. 

Balansio on kokonaisvaltainen diabeteksen hoidon palvelu, joka mahdollistaa hoitoyksiköille kliinisen hoidon tarjoamisen potilaille etänä perinteisen vastaanoton ulkopuolella. 

Integraatio mahdollistaa FreeStyle Libre käyttäjien sensoridatan automaattisen siirron LibreLink pilvipalvelun kautta suoraan Balansioon. Sensoridataa käytetään yhdessä potilaan muun Balansioon kerätyn omahoitodatan kanssa. Balansio analysoi ja korostaa automaattisesti ongelmakohdat hyödyntäen automatisoitua kliinistä analyysiä. Tämä mahdollistaa sekä potilaan että terveydenhuollonammattilaisten kohdentaa hoidolliset toimenpiteet löydettyihin ongelmiin sekä huomioida onnistuneet parannukset. 

Balansio mahdollistaa nykyaikaisen, potilaslähtöisen sekä tarpeenmukaisen diabeteshoidon, jonka avulla potilaalle voidaan tarjota hoitoa ja tukea tarvittaessa, osana arkipäiväistä elämää. Tällä tavoin pystytään saavuttamaan parempia hoitotuloksia verrattuna vastaanottokeskeiseen hoitotapaan. Balansio sopii tyyppi 1, tyyppi 2 sekä raskausdiabeteksen hoitoon. Balansio on digitaalinen palvelu (reguloitu sekä CE-merkitty lääkinnällinen laite) julkisen ja yksityisen sektorin diabeteksen hoidon tarjoajille. Balansio sisältää turvatun potilaan datasiirron sekä kommunikointikanavan potilaan ja hoitotiimin välillä. Balansio käyttää omahoitodataa auttaakseen diabeetikkoa oppimaan sekä muokkaamaan omia elämäntapoja, lääkitystä ja hoitorutiineja. Balansio tarjoaa boluslaskimen pikainsuliiniannoslaskentaan, automatisoidun basaalititraattorin oikean perusinsuliinitason löytämiseen sekä päivittäisen HbA1c -estimoinnin hoidon etenemisen seuraamiseen. Balansio on saatavilla Android sekä iOS älypuhelimille. Hoidon ammattilaisille Balansio Pro toimii verkkoselaimessa. 

“Diabeteshoidon tulisi muuttua klinikka-, sekä kalenterikeskeisestä potilaskeskeiseen sekä tarpeen mukaiseen, tuettuun omahoidon malliin. Hoidon ohjaaminen tulisi olla tuloskeskeisempää sekä hoitopäätösten teko tulisi olla dataan perustuvaa. Vaikuttavan hoidon tulisi olla aika- ja paikka riippumatonta potilaalle.”, kommentoi Markku Saraheimo LT, Sisätautilääkäri, Diabetologi, Quattro Folian lääketieteellinen neuvonantaja. “Balansion täysi näkyvyys potilaan tietoihin sekä kliinisen analyysin tuoma apu mahdollistaa diabeetikoille parempaa elämänlaatua, helpottaa päivittäistä diabeteksen hallintaa sekä tehokkaampaa, dataan perustuvaa diabeteksen hoitoa. FreeStyle Libre mahdollistaa vaivattoman ja joustavan glukoosiseurannan sekä tuottaa enemmän dataa diabeetikoiden päivittäiseen verensokeriarvojen hallintaan. Automaattinen avustus sekä näkyvyys potilaan kaikkeen omahoitodataan ovat äärimmäisen tärkeitä hoitohenkilökunnan työkaluja, joiden avulla pystytään tarjoamaan oikea-aikaista tukea.” Saraheimo lisää. 

 

Quattro Folia

Quattro Folia on Suomalainen Startup -yritys, joka kehittää terveysteknologiaa sekä siihen liittyviä digitaalisia palveluja ammattilais- sekä kuluttajakäyttöön. Yrityksen missiona alusta saakka on ollut miettiä uudelleen tapoja hoitaa kroonisia sairauksia digitaalista teknologiaa hyödyntäen. Yrityksen mission toteutuminen näkyy jo ensimmäisessä tuotteessa – Balansiossa, joka asettaa diabeetikon ajajan paikalle sekä mahdollistaa hoidon ammattilaisille oikea-aikaisen ja tarpeenmukaisen hoidon sekä ohjauksen tarjoamisen, kliinisen tekoälyn sekä algoritmien avustuksella. 

Lisätietoa sekä haastattelut: 
Paulus Carpelan
(+358) 50 486 7516 
paulus.carpelan(a)quattrofolia.com
www.balansio.com

 


IN ENGLISH


Libre-Balansio-integration-ENG.png

Press release 25.4.2018

Quattro Folia is authorized by Abbott to provide FreeStyle LibreLink® integration with Balansio® service. 

Quattro Folia, Espoo, Finland., April 25, 2018 – Quattro Folia announced today that its Balansio service is authorized by Abbott to receive data from FreeStyle LibreLink in Finland. The integration is available from 23th of April along with the new Balansio release. 

Balansio is a holistic diabetes management service enabling clinics to extend professional clinical service to their patients remotely outside traditional appointments. The integration enables Balansio users using FreeStyle Libre to get their sensor data through LibreLink cloud service directly to Balansio. Received sensor data together with other holistic self-care data collected by Balansio to be analysed and highlighted by the augmented clinical intelligence enabling both the patient and the healthcare professionals to focus on the issues found and improvements achieved. 

Balansio enables modern patient-centric, need-based care model where the patient receives professional help and guidance in a timely manner as part of their everyday life. This enables better care results compared to appointment driven care model. Balansio supports type 1, type 2 and gestational diabetes care. Balansio is an online service (regulated and CE marked medical device) for professional healthcare service providers and clinics to provide care for people with diabetes including secure data sharing and communication between the patient and the care team. In addition, Balansio automatically assists the patient to learn and adjust their behavior, medication and care routines based on the self-care data. Balansio offers bolus calculator, automated basal titration (type 2) and daily HbA1c -estimation, which helps both the patient and the care team to see the care progress. Balansio supports both Android and iOS smartphones. For professionals, an optimized Balansio Pro application can be used through a web browser. 

“Diabetes care has to be changed from a clinic-centric and calendar-driven care model to a patient-centric and need-based assisted self-care model. The care guidance and medical decision-making need to be data driven and goal-oriented. Effective care needs to be time and place independent for the patient.”, comments Markku Saraheimo, MD, Specialist of Internal Medicine and Diabetology, Quattro Folia’s medical advisor. “Balansio's full data visibility and the help of augmented intelligence provide a better life quality for people with diabetes, makes their daily diabetes management easier and diabetes care data-driven and more effective. FreeStyle Libre enables effortless and flexible glucose monitoring and provides more data for individuals to use in their daily glucose management. Automated assistance and visibility to full patient self-care data for the HCPs is the key to provide timely support.”, Markku adds. 

 

About Quattro Folia

Quattro Folia is a Finland based software startup company focusing on developing professional healthcare technology and related digital services. Company’s mission from the beginning has been to re-think the treatment of chronic diseases by utilizing digital technology. The realization of that mission is Balansio service, which puts the diabetic into the driver seat and enables professional care team to provide timely support and coaching as needed with the help of automation and clinical algorithms. 

More information and interviews:
Paulus Carpelan
(+358) 50 486 7516
paulus.carpelan(a)quattrofolia.com
www.balansio.com

New augmented clinical intelligence solution for assisted diabetes self care

Quattro Folia announces the release of Balansio 2.0, its new, highly automated service to aid people with diabetes and their care teams.

Espoo, Finland – September 9th 2017

Quattro Folia Oy, the leading provider of medical software devices for assisted self-care, today announced the release of Balansio 2.0, a new cloud service for the health care. The Balansio platform, with its revolutionary Augmented Clinical Intelligence capabilities, provides a faster and more efficient way for health care professionals to perform their clinical care activities.

Balansio is designed to make the life of people with diabetes easier. Individuals with diabetes face challenges on daily bases like dosing insulin. At the same time, it is essential to manage also the long-term care balance. The daily task of managing insulin dosages is solved by Quattro Folia’s Bolus Calculator providing diabetics with multiple daily insulin injections treatment the same level of bolus calculator as can be found on insulin pumps. For the long-term care balance of managing the Hemoglobin A1c (HbA1c) level, Balansio reduces the need to get a laboratory test done but Balansio shows daily calculated, highly accurate, continuous A1c estimation.

Balansio helps patients to take control of their condition with the combined support of healthcare professionals and Augmented Clinical Intelligence. The service is designed to transform current appointment-driven care practices into patient need-driven health care, enabling doctors, nurses and other professionals to focus on those patients requiring attention at the moment. This is achieved by the highly automated collection of patients’ self-care data, applying advanced analytics and algorithms, which adapt individually. Patient data and other findings can be accessed by both the patient and the professional. Balansio also provides efficient and secure communication between the patient and the care team.

“Quattro Folia has gained a lot of interest among big pharma and diagnostics companies with our CE certified (class 2b) leading edge bolus calculator” says Vice President of Marketing, Paulus Carpelan. “On this release, we are proud to introduce the CE marked continuous A1c estimator, one of the most accurate in the market place.”

“Balansio provides a data-driven, mobile and individual centric platform. It includes all the basic components for telehealth and device integration needs” says Toni Pakarinen COO of Quattro Folia. “What differentiates us from others is that our platform now has an Augmented Clinical Intelligence layer which enables the efficient use of independent medical device algorithms as well as clinical assistance algorithms.”

 

About Quattro Folia and Balansio

Balansio is developed by Quattro Folia, a high-tech company founded in 2012 focusing on value-based healthcare solutions. Quattro Folia offers Balansio ecosystem for both large and small healthcare service providers who want to transform their current health care services into next generation, value based, time and place independent on-line services.

For further information, please visit the Balansio website at: www.balansio.com
Balansio is a registered trademark of Quattro Folia Oy.

Quattro Folia press contact:
Paulus Carpelan, VP Marketing and New Business Development
Quattro Folia Oy
E-mail: paulus.carpelan(a)quattrofolia.com
Phone: +358 50 486 7516

Ascensia and Quattro Folia to announce partnership

IMG_0130_00_NEXT_LR-300x113@2x.jpg

Ascensia Diabetes Care and Quattro Folia today announced a technology partnership that connects the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) from Ascensia to Quattro Folia’s Balansio Mobile app. By enabling the effortless transfer of highly accurate blood glucose values for insulin calculations, this collaboration aims to optimize insulin management for patients.

Read the full article here

Ilmainen insuliiniannoslaskuri diabeetikkojen käyttöön

Diabetesta sairastaa arviolta jopa puoli miljoonaa suomalaista. Diabeetikon haima ei tuota tarpeeksi elintärkeää insuliinia, mikä vaikuttaa verensokeritasapainoon. Sairaus edellyttää päivittäistä omahoitoa ja usein myös insuliinin annostelua potilaan toimesta, mm. aterioinnin yhteydessä. Amerikassa tehdyn tutkimuksen mukaan 63% insuliinihoitoisista diabeetikoista ei kuitenkaan osaa laskea aterialla tarvittavaa insuliinimäärää oikein. Tämä aiheuttaa verensokeritasojen heittelyä, mikä vaikeuttaa arkea, heikentää hoitotuloksia ja lisää erilaisten johdannaissairauksien vaaraa. Pahimmillaan virhearviot ovat hengenvaarallisia.

Balansio-CareSens.001-225x300@2x.png

Suomalaisyritykset Quattro Folia ja Medcase ovat kehittäneet yhdessä ratkaisuja, joilla päästään parempaan hoitotasapainoon sekä vahvistetaan diabeetikon omahoitoa ja oppimista. Ensimmäinen ratkaisu on CareSens-verensokerimittareiden käyttäjille tarjottu, älypuhelimessa toimiva Balansio-ateriainsuliinilaskuri. Ratkaisu on jo tarjolla veloituksetta julkisen terveydenhuollon kautta mm. Helsingissä, Tampereella ja Pirkanmaalla, Kotkassa, Kouvolassa, Oulussa sekä Pohjois-Suomessa.

Insuliiniannoksen arvioiminen on jokapäiväinen ja toistuva haaste

Insuliinilla hoidettavat diabeetikot joutuvat laskemaan jokaisen nauttimansa suupalan sisältämän hiilihydraattimäärän ja tekemään päätöksen insuliiniannoksesta kymmeniäkin kertoja vuorokaudessa. Quattro Folia ja Medcase tarjoavat ratkaisuksi yhdistelmää, jossa perusterveydenhuollon maksamat CareSens-verensokerimittarit kytkeytyvät langattomasti älypuhelimessa olevaan, suomenkieliseen Balansio-insuliinilaskuriin. Laskuri suorittaa ateriainsuliinilaskennan diabeetikon puolesta ja sitä voi käyttää helposti älypuhelimen ruudulta tai yhteensopivasta älykellosta.

Mahdollisuus hoidolliseen loikkaan

CareSens-verensokerimittareita edustavan Medcasen toimitusjohtaja Janne Sirén uskoo tuetun omahoidon merkityksen vain kasvavan: ”Harvassa sairaudessa potilas itse tekee yhtä paljon lääkkeen annostukseen liittyviä päätöksiä kuin diabeetikot. Vaikka monista diabeetikoista väistämättä kasvaa sairautensa parhaita asiantuntijoita, sairaus aiheuttaa jatkuvaa päänvaivaa. Älypuhelin kulkee useimmilla aina mukana, joten se on luonteva väline taakan keventämiseksi. Tulevaisuudessa tarjoamme diabeetikoille vieläkin enemmän työkaluja arjen helpottamiseksi.”

Uuden yhdistelmäratkaisun ansioista diabeetikoilla on mahdollisuus paremmin hallita insuliinin käyttöään ja siten parantaa elämän laatuaan sekä hoitoennustettaan, kertoo Balansio-sovellusta kehittävän Quottro Folian toimitusjohtaja Harri Okkonen. ”Balansio palvelu on tarjolla myös hoitoyksiköille, hoitotiimi näkee diabeetikon tuottaman omahoitotiedon. Hoitotiimi voi tiedon pohjalta viestittää palvelun kautta diabeetikolle opastusta ja ohjeita. Palvelun käyttöönotto tarjoaa merkittävän mahdollisuuden hoidolliseen loikkaan, sitä mukaa kun hoitoyksiköt ottavat palvelun käyttöönsä. Ajasta ja paikasta riippumaton ratkaisu tasa-arvoistaa potilaiden hoidon tasoa asumispaikasta riippumatta.”

Lisätietoja

Lisätietoja aiheesta antavat toimitusjohtaja Harri Okkonen Quattro Folia Oy:stä (+358 44 555 2626) sekä toimitusjohtaja Janne Sirén Medcase Finland Oy:stä (+358 44 522 3690).

Yritykset ratkaisujen takana

CareSens ja Medcase Finland Oy

Medcase on CareSens-verensokerimittareiden virallinen edustaja Suomessa sekä Quattro Folian kumppani CareSens- ja Balansio-tuotteiden yhteishankkeessa. CareSens on Suomen toiseksi suosituin verensokerimittarituote (Sailab ry:n tilastot), joka on käytössä laajalti eri puolilla maata. CareSens-verensokeri- ja ketoainemittarit ovat mobiilikytkennän edelläkävijöitä ja ne voidaan kytkeä älypuhelimiin mm. langattomalla Bluetooth Low-energy -tekniikalla. CareSens-verensokerimittarit ovat erittäin tarkkoja, ne ylittävät viimeisimpien ISO 15197:2013- sekä EN ISO 15197:2015 -mittaustarkkuusstandardien vaatimukset.

Quattro Folia Oy

Quattro Folia on vuonna 2012 perustettu terveysteknologiayritys. Quattro Folia tuottaa ohjelmistoratkaisuja pitkäaikaissairaiden omahoidon tehostamiseen ja tarjoaa terveydenhuollon ammattilaisille uuden tavan tarjota tehokasta ja ennaltaehkäisevää etähoitoa. Balansio on Quattro Folian kehittämä ja CE-merkitty lääkinnällinen ohjelmistoratkaisu diabeteksen tuettuun etähoitoon. Balansio mahdollistaa automaattisen verensokeri- ja muun mittaustiedon siirtämisen ja hyödyntämisen uusissa hoitomenetelmissä.

 
79C19924-68BE-499F-9FBB-A2439A8E1649-300x75@2x.jpeg
medcase-logo-300x67@2x.png
Balansio-modified.001-300x109@2x.jpeg
caresens-logo-300x40@2x.png
 

Balansio service is being tested in a remote care trial of DigiSote project. 

DigiSote+Balansio (1).png
 

Quattro Folia is participating in North Karelian DigiSote trial. The trial focuses on remote care for diabetics. DigiSote is funded by European Social Fund (ESF) and it is one of the biggest ongoing health care projects in Finland. In the trial, current best practices are being challenged and iterated by utilizing new types of services, care practices and technology. The purpose of DigiSote is to find new innovative solutions for the public health care sector in North Karelia.

During the trial, health care professionals and individuals with diabetes use Balansio service to gain new insights of remote care in diabetes management. Balansio ́s built-in insulin dosage calculator is used as part of the trial to gain and maintain a better glycemic control. The trial began on 11.5.2017 and will continue for three months. The trial ́s purpose is to find out how a remote care service, such as Balansio, affects the patients’ care balance and motivation as well as how it affects the work efficiency and experience of the health care professionals.

 

More information

http://www.karelia.fi/digisote/

https://www.facebook.com/pkdigisote

https://twitter.com/pkdigisote

https://www.instagram.com/pkdigisote/

www.balansio.com

Future of Diabetes Management – Recap of ATTD 2017

Written by Petteri Väisänen, Research Engineer at Quattro Folia.

As a biomedical engineer working on improving diabetes management, my favourite event is definitely the annual conference of Advanced Technologies & Treatments of Diabetes (ATTD). It was held from 15th to 18th of February, 2017 in Paris, France. Although, the scenery around downtown is full of history, the actual conference is really about the future! And in this case, the future of diabetes management. Next is my view of things that will be part of the future…

Since many of the presentations at ATTD started with the same slide, I find it only appropriate to start with the same figure. Thanks to T1D Exchange, there is now relevant data of the status of glycemic control in USA [1]. Figure 1 shows the average A1c among the type 1 diabetics and the figure is alarming. The findings show that there is an significant gap between the recommendations set by American Diabetes Association (ADA)  and the actual A1c values of type 1 diabetics. As an example, ADA recommends that diabetics in the age of 16-18 should have an A1c value of 7,5% (58 mmol/mol) [2]. However, the actual mean value is around 9% (75 mmol/mol). There is no question that these high values will have consequences, not only for the individuals themselves, but also for the society and economy. For instance, diabetes (and especially poorly managed) is shown to have impact on productivity, absenteeism and early retirements [3].

Mean-A1c-for-T1D-in-USA.001.png

Figure 1: Solid line is showing the average hemoglobin A1c (the biomarker of glycemic control) by age among the type 1 diabetics in USA (n=16,057) [1]. The dashed line is showing American Diabetes Association (ADA) guidelines for adolescents and adults [2].

It is important to remember that diabetes management is not all about the A1c, but most of us have seen the figure with the exponential risks for secondary diseases that is related to poor glycemic control shown in DCCT study [4]. Furthermore, there is evidence showing that the prior glycemic control has sustained negative effect, even though the control is returned to normal. This is known as “metabolic memory” [5,6,7]

But enough of the gloomy part… Let’s open the door for brighter future and things that may improve individual’s diabetes management. Below is few highlights from ATTD.

Continuous glucose monitoring (CGM), including flash glucose monitoring (FGM)

Okay, CGM and FGM are nothing new, but they are here to stay. Hopefully in future, they will have a wider user base. There are plenty of studies that shows the benefits of CGM [8], and not only for T1D, but also for T2D [9]. Furthermore, CGM can be cost-effective option for even those T2D who do not use prandial insulin as a form of treatment [10]. In the case of CGM devices, there are two major positive things. Firstly, the manufacturers are eager to develop ways to improve the accuracy of meters, even with less calibration measurements. Increased accuracy will allow CGM to be used for treatment decisions also. Secondly, the increasing competition makes CGM accessible for more diabetics.

Insulin pumps and insulin types

Again, not a totally new thing, but there is some serious potential in these! Device manufacturers are trying to find ways to speed up the insulin absorption with pumps. They are developing solutions e.g. for dispersed injections, ways to tackle Tamborlane effect, intraperitoneal infusion, or even by warming the infusion-site. Insulin manufacturers offer wide variety of things to discuss, but let’s pick the most prominent: Ultrafast insulins! For instance, faster-acting aspart shows 25.7 minutes’ improvement on peak-time when compared to the insulin aspart on the market today and thus, better mimics the endogenous secretion of insulin [11].

Diabetes management software

This is where the magic happens! We have had the technology to connect pumps, meters and sensors to mobile devices for a long time. Now the devices are actually connected which enables applications to find ways to improve glycemic control. One that I have to mention is Artificial Pancreas (AP); a system that consists of an insulin pump, CGM, and a control device (including control algorithm). Many are aiming to have fully automated closed-loop control systems that would mimic the functions of human pancreas as much as possible. Although that might be far away, hybrid closed-loop algorithms are already here and some are already FDA approved [12]. You might only need to do as little as “announce a meal”, and the system does the rest… almost. There are cases where intensive exercise brings challenges to the controlling algorithms. And with the AP, the competition lies in the controlling algorithm. Who has the most efficient control algorithm which is also safe to use in all cases? Well, we still have to wait for the evidence from multiple studies that are ongoing, but I will say this: The competition is a promise of results!

Artificial-pancreas.png

Figure 2: An artificial pancreas system; the insulin pump is controlled with algorithm that can be in separate control device or in mobile phone. The algorithm has glucose sensor data as input but in future inputs can include factors such as insulin data, activity, and geolocation.

Before fully automated closed loop control is achieved, there are some tools that people with diabetes are shown to benefit from. For instance, the insulin bolus calculation is not that easy as one might think. Study shows that 63% of manually calculated doses were incorrect [13]. One way to solve this problem is to use a bolus insulin calculator that has been proven to provide correct values while taking into account carbs, exercise, and personal factors.

Second example is basal insulin titration for T2D that can be done though certified application. In result, the health care professional´s burden is reduced while the patients’ fear of hypoglycemia is also reduced [14,15]. Patients feel more engaged to the treatment because the application can educate as well as motivate the patient throughout the titration process.

Enabling continuous A1c measurement

At ATTD, we had the opportunity to present our latest results of individually adaptive Continuous A1c algorithm. It enables fast care feedback meaning that our algorithm accurately fills unmonitored gaps in glycemic control by using just routine monitoring data. By doing so, individuals with diabetes get timely feedback about their care quality since they can see how their individual A1c value changes. This is a feature that we are really excited about and plan to release it on the next version of Balansio Mobile. For more information about the Continuous A1c algorithm, click the link below to see our poster that we presented in Paris.

View the poster here

To conclude, data-driven and connected self-care is the future. Algorithms, such as Continuous A1c, are here stay and to improve diabetes management. Yet, the algorithms are only tools and diabetes management is a lot more than equations. This is why we are working hard to bring the interactive and educational support for all diabetics.

REFERENCES:

[1] Miller et al. Diabetes Care 2015; 38:971-978

[2] Chiang et al. Diabetes Care 2014; 37:2034-2054

[3] Breton et al. Diabetes Care 2013; 36:740-749

[4] Skyler JS. Endocrinol Metab Clin North Am 1996; 25:243-254

[5] Berezin A. Diabetes Metab Syndr 2016; 10:176-183

[6] Cerielle et al. J Clin Endocrinol Metab 2009; 94:410-415

[7] Aschner & Ruiz. Diabetes Technol Ther 2012; 14:68-74

[8] Liebl et al. J Diabetes Sci Technol 2013; 7:500-519

[9] Meade LT. Diabetes Technol Ther 2012; 14:190-195

[10] Fonda et al. J Diabetes Sci Technol 2016; 10:898-904

[11] Heise et al. Diabetes Obes Metab 2017; 19:208-215

[12] FDA approval of Medtronic Minimed 670G system 2016; P160017

[13] Sussman et al. J Diabetes Sci Technol 2012; 6:339-344

[14] Hsu et al. Diabetes Technol Ther 2016; 18:59-67

[15] Sieber et al. ADA 2016; 1219-P

Balansio + CareSens Dual ja CareSens N Premier

Balansio-CareSens-.001.jpeg

Oletko koskaan miettinyt helpompaa tapaa kirjata verensokerimittauksia? Jos ei ylipäänsä tarvitsisi kirjoittaa mitään? Jos vain tekisi mittauksen ja tieto tallentuisi jonnekin, mistä sen voisi tarvittaessa nähdä, esim. älypuhelimeen.

Bluetooth-toiminnolla varustettuja CareSens-mittareita on alettu jakaa jo usean kaupungin hoitotarvikejakelupisteissä, ja niitä löytää myös kotimaisista verkkokaupoista. Balansio Mobile -sovellus tukee CareSens-mittareita ja tekee samalla omaseurannastasi huomattavasti helpompaa.

CareSens Dual ja CareSens N Premier

 
medcase_caresens_dual_highres-4-226x300@2x.png
medcase_caresens_n_premier_highres-1-225x300@2x.png
 

Yksinkertaisesti selitettynä, verensokerimittari paritetaan älypuhelimeesi ladatun Balansio Mobile -sovelluksen kanssa. Tämän jälkeen verensokerimittaukset siirtyvät automaattisesti ja langattomasti mittarista sovellukseen. Tiedot siirtyvät tietoturvallisesti omalle käyttäjätilille. Helppoa eikö vain?


Mitä hyötyjä Balansio-sovelluksesta ja CareSens-mittareiden käytöstä on sinulle?

Balansion tarkoitus on helpottaa diabeetikon arkea ja tarjota tarvittavat työkalut diabeteksen omaseurantaan. CareSens N Premier mittarin avulla saat siirrettyä verensokeritiedot langattomasti, ja CareSens Dual mittarin avulla voit verensokerimittausten lisäksi tehdä ketoainemittauksia.

Balansio ja CareSens yhdistelmä poistaa tarpeen merkitä verensokerimittaustiedot vihkoon tai muuhun sovellukseen manuaalisesti. Teet vain mittauksen, ja kun poistat liuskan mittarista, siirtyy tieto puhelimeen.

Yhdistelmä sopii myös henkilöille jotka innolla seuraavat omia tietojaan ja haluavat saada kaikki verensokeritasoon vaikuttavat tekijät yhteen näkymään. Balansioon saat kirjattua myös hiilihydraattitiedot, pika- ja pitkävaikutteiset insuliinit, painon ja muistiinpanoja. Jos harrastat paljon liikuntaa ja käytät urheilusovelluksia voit tuoda myös liikuntatiedot automaattisesti Balansioon Google Fit (Android) tai Health (iOS)-sovellusten kautta. Tallennetut tiedot näkyvät visuaalisesti Balansiossa ja auttavat hahmottamaan kokonaiskuvaa omahoidosta ja sen ongelmakohtia.

Viimeinen arkea helpottava toiminto on myös Balansion sisältämä pikainsuliinin annoslaskuri. Laskuri on CE-sertifioitu lääkinnällinen laite ja auttaa arvioimaan pikainsuliiniannokset nopeasti arjen tohinassa. Sinun tarvitsee syöttää vain verensokeriarvosi (jonka saat automaattisesti CareSens-mittarista) ja arvioitu hiilihydraattimäärä ruokailun yhteydessä. Kattavien asetusten ansiosta arviot ovat luotettavia ja tarkkoja.


Mistä CareSens-mittarin ja Balansion saa käyttöön?
 

CareSens Dual

  • Haminan hoitotarvikejakelu
  • Helsingin hoitotarvikejakelu (tulossa)
  • Kotkan hoitotarvikejakelu
  • Tampereen hoitotarvikejakelu (tulossa)

CareSens N Premier

  • Helsingin hoitotarvikejakelu (tulossa)

Verkkokaupat

Balansio

Balansio on ilmainen ja ladattavissa Google Play -kaupasta ja AppStoresta. Tällä hetkellä CareSens-tuki löytyy vasta Android-sovelluksesta. Tulemme päivittämään iOS-version vuoden 2017 alussa, jotta molemmat järjestelmät tukevat CareSens-mittareita.

Lataa Balansio Android-puhelimelle tästä:
Lataa

Lataa Balansio iPhonelle tästä:
Lataa

Research | Reducing hypo risk by using cloud based diabetes management solution

Reducing-hypoglycemia-risk-by-using-cloud-based-diabetes-management-solution.jpg

Title 

Reducing hypoclycemia risk by using cloud based diabetes management solution

Presented

Advanced Technologies & Treatments for Diabetes (ATTD), Milan, Italy, February 2-6, 2016

Briefly 

Fear of hypoglycemia may affect user´s daily diabetes management. Study showed that with the help of a cloud based diabetes management system, user can learn to reduce the risk of hypoglycemia while also lowering the HbA1c level. Active communication between the user and the health care professional increased the user’s motivation towards the treatment. Also, the visualisation of data helps the user to understand his body’s causalities.

Research | Continuous estimation of HbA1c with routine monitoring data.

Continuous-estimation-of-HbA1c-with-routine-monitoring-data-768x543@2x.jpg

Title 

Continuous estimation of glycosylated hemoglobin (HbA1c) with routine monitoring data.

Presented

8th Euro Global Diabetes Summit and Medicare Expo, Valencia, Spain, November 4-6, 2015

Briefly

When A1c is measured 2-4 times in a year, diabetes management has unmonitored gaps. Continuous A1c algorithm can fill the gaps between laboratory A1c measurements. Robustness and accuracy evaluation showed that algorithm is able to calculate continuous A1c reliably for diabetics with regular self-monitoring blood glucose measurements, and algorithm works even with biased measurement patterns. Therefore, continuous A1c algorithm can be used to guide in day-to-day diabetes management.

Challenges with insulin calculators and how Balansio Mobile compares to the competition

The recent study shows that finding good insulin calculators can be more challenging than you might think. In this post, we will walk through the main issues of the most popular insulin calculators that are used for diabetes self-care. At the same time, we will explain how Balansio Mobile´s insulin calculator differs from the competition.

In our work together with consumers, we have noticed that many people are skeptic about using insulin calculators or other diabetes-related applications in their daily life. The same goes for medical professionals even though many consider that applications such as bolus calculators could have the potential to help users to manage their condition. What makes the situation more confusing is a study1 which shows that more than 60 % of diabetics do not know how to calculate their required bolus insulin amount or have trouble calculating it correctly.

Based on our own experience when working with diabetics, we discovered that it is because of two main reasons; required effort and reliability. The key aspect that users are looking for is easier and hassle-free way to manage their condition. In addition, the application must be reliable.

Required effort and Reliability

For most health apps that exist on the market, there is a trade-off between required effort and level of trust. An application is either quick and easy to use but does not take into account all possibilities that can occur during the day and/or has some features that can show insufficient or incorrect information. The reasons for simple apps can be many, but one major reason is to make the app as effortless as possible for the user. Insulin-dependent diabetics are required to constantly add data about themselves in order for apps to have enough information to give an insulin proposal. The process of saving the information needs to be as smooth as possible in order for it to fit in with the other diabetes-related tasks (e.g. manually measuring blood glucose level, count carbohydrates and injecting insulin, to name a few). Therefore, it is no surprise that developers want and need to make as simple and easy to use applications as possible.    

GalaxyS5_Mockup-1.jpg

On the other hand, some applications allow users to add detailed information that enables to use the apps in various everyday situations. The challenge with detailed information is that it increases the efforts to use the application. In other words, Each data input requires too many taps, swipes and saves for it to be called “easy to use”. In many situations, this can end up with the user uninstalling the application.

Besides the required effort to use an app, reliability also plays a big role. This is in many ways obvious since the main reason for using an insulin calculator is get a correct answer every time. Unfortunately, many applications, many of which lack proper certification, have not been tested enough. Incorrect bolus insulin proposals can have serious and even life-threatening consequences.    

Balansio is effortless and reliable

Like most other insulin calculators Balansio is a bolus calculator for insulin-dependent diabetics. It is designed to be used multiple times a day and hence, the way to input data is optimized to the core data needed. Instead of adding many details of information with every input, Balansio relies on defining ones settings thoroughly before taking the application into use. After defining the settings Balansio adjusts its calculation algorithm based on the time of the day and events that occur during the day. Because of this the user only needs to tap her blood glucose value and carbohydrate intake and accept or adjust the bolus proposal before saving the data. It takes less than 5 seconds to input and save the data with Balansio, which is important when you are about to start a lunch and don’t want to play around with applications.

Despite being easy to use, the goal is also to be reliable without cutting corners on providing trustworthy and accurate information. This should be achieved regardless of the time of day or what the user has eaten earlier. Balansio understands the possible variation of the way user’s body reacts to insulin and carbohydrates eaten as well as the need for different target blood glucose ranges throughout the day. The bolus proposal is always provided accordingly. Balansio incorporates a number of safeguards protecting the user from inputting inappropriate data entries as well as limits the bolus proposals as defined in the settings. Bolus proposal is not provided if any of the safeguards are triggered.

The competition

A recent study2 of currently available applications on the market which provide bolus proposals shows that over 95% of the applications have issues, which makes the applications unreliable to use. Table 1 (from the study) shows in detail what kind of issues were found from the products. The table is divided into three issue types consisting of input issues, output issues, and other software errors. Each individual issue is further explained in comments. The percentage of applications impacted by the issues are shown next. Finally, a description of how Balansiocompares to the issues is presented.

Balansio_blog_reliablility-of-insulin-calculator-709x1024.jpg

According to the study shown on table 1, 96% of bolus calculators available on the market contain at least one issue with data input affecting the bolus calculation. Furthermore, 67 % of the tested apps had at least one output issue, e.g. 48 % violated a clinical model. Finally, nearly a quarter of the applications kept crashing or did not respond to commands during testing. In comparision, we feel confident saying that Balansio is not characterized by any of the issues mentioned in table 1. Even though Balansio has not yet gone through a similar test, due to its resent launch, both input and output issues mentioned have been taken into account during the development. For example, Balansio has shown to consistently follow the stated formula and the output is synchronised with changing user input. Extensive testing has been performed to ensure the application functionalities and ensure that the application does not unexpectedly crash during use. In other words, there is a reason for Balansio being a CE certified class 2b medical device.

To wrap it up

Although many insulin dependent diabetics seem to find it challenging to estimate their bolus insulin dosages correctly, there seems to be a mistrust for bolus calculator applications that exist on the market. The mistrust seems to be valid because a recent study shows that over 95 % of insulin calculators have at least one issue due to which the apps may show incorrect data. Balansio offers reliable and easy to use CE-certified medical device application for insulin dependent diabetics looking for a bolus insulin calculator for daily use.

REFERENCES

  1. Sussman et al., 2012 – Performance of a Glucose Meter with a Built-In Automated Bolus Calculator versus Manual Bolus Calculation in Insulin-Using Subjects
  2. Kit Huckvale et al., 2015 – Smartphone apps for calculating insulin dose: a systematic assessment

WRITTEN BY

Paulus Carpelan, VP of Product Marketing
Otto Elonen, Business Development Manager

Quattro folia has launched balansio mobile, a ce certified mobile application for diabetes care

Espoo, Finland – Quattro Folia Oy has today launched Balansio Mobile, an application designed for insulin dependent diabetics to calculate bolus insulin dosages several times day.

Balansio Mobile changes the way how insulin dependent diabetics can handle their condition. Based on resent studies over 50% of diabetics using bolus insulin do not know how to calculate required bolus insulin amount correctly. By using the Balansio Mobile application user don’t need to remember their previous blood glucose measurements, eaten carbohydrates, bolus insulin dosages taken, etc. Balansio Mobile takes all relevant data into account when providing the bolus proposal for the user.

Compared to majority of available bolus calculators, Balansio Mobile has a number of safety measures implemented to prevent inappropriate bolus proposals. In addition, it enables the user to set personalized possible range for the bolus proposal.

Balansio Mobile is a CE certified class 2b medical device.

Balansio Mobile is available on Google Play free of charge.

About Quattro Folia
Quattro Folia Oy is a privately owned Finnish software company. Quattro Folia offers
solutions for supported self-care for individuals with chronic diseases. All Quattro Folia’s
software is produced and procured in compliance with the company’s EN ISO 9001 and
EN ISO 13485 certified Quality Management System.

Writer

Harri Okkonen
CEO of Quattro Folia